'CES First Participation' SK Biopharm Wins Innovation Award with Wearable Device

President Donghoon Lee Holds First Meeting with US Kala Health
"Will Strengthen Strategic Partnership in DTx"

On the 6th, at the world's largest electronics and IT exhibition 'CES 2023,' Chey Tae-won, Chairman of SK Group (right), visited the booth and personally experienced SK Biopharm's wearable device, 'Zero GlassTM.' / Photo by SK Biopharm

[Asia Economy Reporter Myunghwan Lee] SK Biopharm announced on the 9th that it successfully completed its first participation in CES 2023, the world's largest electronics and IT exhibition held in Las Vegas, USA, from the 5th to the 8th (local time).

During the four-day exhibition, SK Biopharm showcased five types of wearable devices developed in-house for epilepsy patients, providing visitors with the opportunity to experience them firsthand.

In particular, SK Biopharm's self-developed 'Zero GlassTM' and 'Zero WiredTM' received the CES Innovation Award, becoming the first domestic pharmaceutical company to do so, thanks to their outstanding design and technology. These wearable devices, developed in various forms to suit patients' lifestyles, record biometric signals in real time on the 'Zero AppTM' and allow for data analysis.

On the second day of the exhibition, the 6th, SK Group Chairman Chey Tae-won visited the booth, personally experienced the glasses-type wearable device 'Zero GlassTM,' and encouraged SK Biopharm to strengthen its business in the high value-added digital healthcare industry, SK Biopharm explained.

Additionally, SK Biopharm President Lee Dong-hoon held a first on-site meeting with Rene Ryan, President of the U.S. digital therapeutics company 'Kalaa Health,' to discuss strengthening strategic partnerships in the digital therapeutics (DTx) field. Kalaa's digital wearable treatment device for essential tremor, 'Kalaa Trio,' was also exhibited at SK Biopharm's CES booth to solidify their cooperative relationship.

President Lee stated, "The five types of wearable devices we developed ourselves mark the beginning of digital healthcare and will be a starting point to become a game changer in the epilepsy field through synergy with the innovative drug cenobamate. We will secure innovative technologies through strategic investments and various open innovations to enhance differentiated value as a global healthcare company and establish a foundation for sustainable growth."

Lee Dong-hoon, President of SK Biopharm, and Renee Ryan, President of Clara Health, are discussing ways to collaborate between the two companies during their first meeting on the 6th. Photo by SK Biopharm